# flaA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *flaA* gene encodes flagellin, the primary structural protein of bacterial flagella, essential for motility and host colonization. Flagellin is recognized by host immune receptors TLR5 and NAIP/NLRC4, triggering innate immune responses and inflammation.
- *flaA* expression is tightly regulated by sigma factors (σ²⁸/FliA) and modulated by environmental cues like c-di-GMP and host factors (e.g., FlgM), ensuring flagellar assembly only when the secretion system is competent.
- Pathogenic mutations in *flaA*, particularly in the D1 and D0 domains, can lead to immune evasion by disrupting TLR5 or inflammasome binding, contributing to chronic infections or altered disease phenotypes like Guillain–Barré syndrome.
- Flagellin's immunogenic properties make it a target for therapeutic interventions, including monoclonal antibodies that neutralize motility and block TLR5 signaling, and its use as an adjuvant in vaccine development to enhance immune responses.
- Post-translational modifications, such as O-glycosylation of *C. jejuni* flagellin with pseudaminic acid, are critical for filament assembly and can influence immunogenicity and host interactions, with glycosylation-deficient mutants exhibiting altered virulence.
- The hypervariable D2/D3 domains of flagellin are responsible for antigenic variation and species-specific host cell adhesion (e.g., *P. aeruginosa* flagellin binding to asialo-GM1), contributing to immune evasion and pathogen tropism.

---

## Executive Summary & Key Metadata

The *flaA* gene encodes flagellin, the principal structural subunit of the bacterial flagellar filament. Flagellin is a globular protein that polymerizes into a helical filament, functioning as a molecular propeller that drives bacterial motility, chemotaxis, and host colonization. Beyond its mechanical role, flagellin is a potent pathogen-associated molecular pattern (PAMP) recognized by host Toll-like receptor 5 (TLR5) and the NAIP/NLRC4 inflammasome, making it a central node in host–pathogen interplay. The protein’s intrinsic ability to elicit strong innate immune responses has positioned *flaA* as a target for vaccine adjuvant development and as a biomarker for bacterial infection diagnostics. This manual provides a comprehensive, biophysically detailed reference on the genomic architecture, structural biology, signaling networks, pathogenic mutations, and therapeutic targeting of *flaA*.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | flaA |
| **UniProt Accession** | C0XTM5 |
| **Representative PDB ID** | true (multiple structures available; see Section 2) |
| **Chromosomal Locus** | Species-dependent; in *Campylobacter jejuni* NCTC 11168, located on the main circular chromosome (locus Cj1339); in *Pseudomonas aeruginosa* PAO1, at PA1092 |
| **Primary Molecular Function** | Structural constituent of flagellar filament; TLR5 agonist; inflammasome activator |
| **Disease & Pathology Associations** | Gastroenteritis (*Campylobacter* spp.), sepsis, bacteremia, ventilator-associated pneumonia (*Pseudomonas*), urinary tract infections (*E. coli*), autoimmune cross-reactivity (Guillain–Barré syndrome) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Genomic Coordinates and Context

The *flaA* gene is not universally conserved in a single chromosomal locus across bacterial species; its position is highly variable and often linked to flagellar regulons. In *Campylobacter jejuni* subsp. *jejuni* NCTC 11168, *flaA* (Cj1339) resides on the circular chromosome at approximately 1,245,000–1,246,500 bp (NCBI RefSeq NC_002163.1). It is flanked upstream by *flaB* (Cj1338), a paralogous flagellin gene, and downstream by *flaG* (Cj1340), a putative flagellin chaperone. The *flaA*/*flaB* tandem arrangement is a conserved feature among *Campylobacter* species and contributes to antigenic variation via gene conversion.

In *Pseudomonas aeruginosa* PAO1, *flaA* (PA1092) is located at ~1,180,000 bp on the chromosome, within the large flagellar regulon that includes *fleQ*, *fleS*, *fleR*, and *fliA* (sigma-28 factor). The promoter region contains a σ²⁸-dependent consensus sequence (TAAA-N15-GCCGATAA) recognized by FliA, which drives high-level expression during late exponential phase when flagellar assembly is maximal.

### 1.2 Promoter Architecture and Transcription Factor Binding

The *flaA* promoter is a classic class III flagellar promoter, dependent on the alternative sigma factor σ²⁸ (FliA). In *C. jejuni*, the promoter contains a canonical −10 (GCCGATAA) and −35 (TAAA) box, with a 15-bp spacer. Binding of σ²⁸ is antagonized by the anti-sigma factor FlgM, which sequesters σ²⁸ until the hook-basal body (HBB) complex is completed. Upon HBB completion, FlgM is secreted through the flagellar export apparatus, freeing σ²⁸ to transcribe *flaA* and other late flagellar genes. This regulatory cascade ensures that flagellin is synthesized only when the secretion system is structurally competent.

Additional regulatory inputs include:

- **FleQ (c-di-GMP sensor):** In *P. aeruginosa*, FleQ represses *flaA* transcription when bound to c-di-GMP, linking flagellar gene expression to biofilm formation. High c-di-GMP levels promote FleQ-mediated repression, while low levels derepress the flagellar cascade.
- **CsrA (carbon storage regulator):** In *E. coli* and *Salmonella*, CsrA binds to the 5' untranslated region (UTR) of *flaA* mRNA, enhancing its stability and translation. CsrA activity is modulated by the small non-coding RNAs CsrB and CsrC.
- **H-NS (histone-like nucleoid structuring protein):** In enteric bacteria, H-NS silences *flaA* under non-permissive conditions (e.g., low temperature, high osmolarity) by binding to AT-rich regions upstream of the promoter.

### 1.3 Enhancer Elements and Chromatin-like Architecture

Although bacteria lack true enhancers, upstream activating sequences (UAS) have been identified in *flaA* promoters. In *C. jejuni*, a 100-bp AT-rich region upstream of the −35 box enhances transcription by facilitating DNA bending, which is mediated by the integration host factor (IHF). IHF binding introduces a sharp kink in the DNA, promoting RNA polymerase–σ²⁸ complex formation. In *P. aeruginosa*, a similar UAS is recognized by the two-component regulator FleR, which binds as a phospho-activated dimer and recruits RNA polymerase to the *flaA* promoter.

### 1.4 Alternative Splicing and Isoforms

Bacterial *flaA* genes do not undergo eukaryotic splicing; however, post-transcriptional modifications generate functional isoforms:

- **Glycosylation variants:** In *C. jejuni*, *flaA* is O-glycosylated at up to 19 serine/threonine residues by the Pse (pseudaminic acid) pathway. The glycosylation pattern is phase-variable, producing multiple glycoforms that alter immunogenicity and motility. The glycosylation sites are clustered in the surface-exposed D2/D3 domains (see Section 2).
- **Proteolytic processing:** The N-terminal methionine is removed by methionine aminopeptidase, and the mature protein is exported via the type III secretion system (T3SS) where it polymerizes at the distal tip of the growing filament.
- **Phase variation:** In *C. jejuni*, a homopolymeric tract of G's in the *flaA* promoter region undergoes slipped-strand mispairing, leading to ON/OFF switching of expression. This stochastic variation generates a heterogeneous population, facilitating immune evasion.

### 1.5 Pseudogenes and Paralogues

*flaA* has a closely related paralog, *flaB*, which shares ~90% nucleotide identity in *C. jejuni*. *flaB* is expressed at lower levels and its promoter is weaker, but gene conversion between *flaA* and *flaB* generates antigenic diversity. In *Helicobacter pylori*, *flaA* and *flaB* are both essential for full motility; *flaA* forms the filament body while *flaB* localizes to the proximal region near the hook. In *P. aeruginosa*, *flaA* is the sole flagellin gene, but a second locus, *flaB* (PA1093), encodes a minor flagellin-like protein of unknown function.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

Flagellin from *C. jejuni* (UniProt C0XTM5) is a 576-amino-acid protein with a molecular weight of ~59 kDa (including glycosylation). The primary sequence can be divided into four major domains:

| **Domain** | **Residues (C. jejuni numbering)** | **Function** |
|---|---|---|
| **D0 (N-terminal α-helix)** | 1–45 | Filament core formation; coiled-coil interactions |
| **D1 (N-terminal β-sheet)** | 46–180 | TLR5 recognition; structural stability |
| **D2 (Hypervariable region)** | 181–450 | Surface exposure; antigenic variation; glycosylation |
| **D3 (C-terminal β-sheet)** | 451–576 | Filament outer surface; host cell adhesion |

The D0 and D1 domains are highly conserved across bacterial species, while D2 and D3 are hypervariable, exhibiting extensive sequence divergence even among strains of the same species. This domain architecture is critical for flagellin’s dual role: the conserved D0/D1 domains are buried in the filament core and are recognized by innate immune receptors, while the variable D2/D3 domains are surface-exposed and mediate antigenic variation.

### 2.2 Secondary and Tertiary Structure

The crystal structure of *C. jejuni* flagellin (PDB: 6Q4T) reveals a Y-shaped molecule with dimensions of approximately 140 Å × 40 Å × 30 Å. The D0 domain forms a long, kinked α-helix (residues 1–45) that packs against the D1 domain’s two antiparallel β-sheets. The D1 domain consists of a five-stranded β-sheet (β1–β5) flanked by two α-helices (α1, α2), forming a classic immunoglobulin-like fold. The D2 domain is a β-sandwich with a jelly-roll topology, while the D3 domain adopts a β-propeller fold.

The hypervariable D2/D3 domains are connected to the conserved D0/D1 domains by flexible linkers, allowing them to adopt multiple conformations. This flexibility is essential for filament assembly, as the variable domains must accommodate the helical packing of the filament.

### 2.3 Post-Translational Modifications and Structural Consequences

**Glycosylation:** In *C. jejuni*, the D2/D3 domains contain 19 O-glycosylation sites modified with pseudaminic acid (Pse5Ac7Ac) or its derivatives. Glycosylation is catalyzed by the Pse pathway enzymes (PseA–PseI) and is required for proper protein folding, secretion, and filament assembly. Structural studies show that glycosylation stabilizes the D2/D3 domains by forming hydrogen bonds with backbone amides, reducing conformational entropy. Unglycosylated flagellin fails to polymerize and is rapidly degraded by the periplasmic protease DegP.

**Phosphorylation:** Although less characterized, phosphorylation of serine/threonine residues in the D1 domain has been reported in *P. aeruginosa*. Phosphorylation at Thr184 (PAO1 numbering) modulates TLR5 activation, with phosphomimetic mutants (T184E) showing reduced TLR5 signaling.

### 2.4 Structural Comparison Across Species

The flagellin structure is remarkably conserved in its D0/D1 domains, with a root-mean-square deviation (RMSD) of <2 Å between *C. jejuni*, *Salmonella enterica* (PDB: 1UCU), and *P. aeruginosa* (PDB: 5K7I). However, the D2/D3 domains vary dramatically in size and fold:

- *S. enterica* flagellin (FliC) has a 148-residue hypervariable region that forms a β-hairpin-rich domain.
- *P. aeruginosa* flagellin has a 200-residue D2 domain with a lectin-like fold that binds to host glycosphingolipids (asialo-GM1).
- *H. pylori* flagellin has a truncated D2 domain, resulting in a thinner filament.

These structural differences underpin species-specific host interactions and immune recognition.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load flaA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=C0XTM5)

The visualizer allows users to explore the atomic coordinates of *C. jejuni* flagellin (PDB: 6Q4T) in three dimensions. Key features to examine:

- **D0/D1 domains (colored blue/green):** Conserved α-helical and β-sheet regions that form the filament core.
- **D2/D3 domains (colored red/orange):** Hypervariable surface-exposed regions with glycosylation sites.
- **Glycosylation sites (shown as spheres):** Pseudaminic acid moieties attached to Ser/Thr residues.
- **TLR5 binding site (highlighted):** Residues 89–96 and 411–419 (C. jejuni numbering) that interact with TLR5’s leucine-rich repeats.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Flagellar Assembly and Motility

The primary function of *flaA* is to provide the structural subunit for the flagellar filament. The assembly process is tightly regulated and involves a dedicated type III secretion system (T3SS), known as the flagellar export apparatus. The pathway is as follows:

1. **Initiation:** The flagellar basal body (MS ring, C ring, and export apparatus) is assembled in the inner membrane.
2. **Hook assembly:** The hook protein (FlgE) polymerizes to form a flexible universal joint connecting the basal body to the filament.
3. **Substrate switching:** Upon hook completion, the anti-sigma factor FlgM is secreted, activating σ²⁸ and initiating *flaA* transcription.
4. **Filament growth:** Flagellin monomers are synthesized in the cytoplasm, bound by the chaperone FliS, and delivered to the export apparatus. The monomers are translocated through the central channel of the growing filament and polymerize at the distal tip.
5. **Capping:** The filament cap protein FliD prevents premature monomer release and facilitates polymerization.

The resulting filament is a helical propeller that rotates at speeds up to 17,000 rpm in *Vibrio* species, generating thrust for swimming and swarming motility.

### 3.2 TLR5 Signaling and Innate Immune Activation

Flagellin is a potent agonist of Toll-like receptor 5 (TLR5), a transmembrane receptor expressed on the basolateral surface of intestinal epithelial cells, monocytes, and dendritic cells. The interaction is mediated by conserved residues in the D1 domain of flagellin, which bind to the concave surface of TLR5’s leucine-rich repeat (LRR) domain. The binding stoichiometry is 1:1, with a dissociation constant (Kd) of ~3 nM.

Upon flagellin binding, TLR5 dimerizes and recruits the adaptor protein MyD88 via its TIR domain. This initiates a signaling cascade:

```mermaid
sequenceDiagram
    participant F as "Flagellin (flaA)"
    participant T as "TLR5"
    participant M as "MyD88"
    participant I as "IRAK4/IRAK1"
    participant T6 as "TRAF6"
    participant K as "TAK1"
    participant N as "NF-κB"
    participant C as "Cytokines (TNF-α, IL-6, IL-8)"
    F->>T: Binds LRR domain (Kd ~3 nM)
    T->>T: Dimerization
    T->>M: Recruits MyD88 (TIR-TIR interaction)
    M->>I: Activates IRAK4/IRAK1 (phosphorylation)
    I->>T6: Recruits TRAF6 (K63 ubiquitination)
    T6->>K: Activates TAK1 (phosphorylation)
    K->>N: Phosphorylates IKK complex → IκBα degradation
    N->>N: Nuclear translocation
    N->>C: Transcriptional activation of pro-inflammatory genes
```

The NF-κB pathway leads to the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-8) and chemokines, recruiting neutrophils and macrophages to the site of infection. Flagellin also activates the MAPK pathway (ERK, JNK, p38) via TRAF6, further amplifying the inflammatory response.

### 3.3 NAIP/NLRC4 Inflammasome Activation

In macrophages, cytosolic flagellin is sensed by the NAIP (NLR family apoptosis inhibitory protein) receptors, specifically NAIP5 and NAIP6 in mice (NAIP in humans). NAIP5/6 bind to flagellin’s D0 domain, which is exposed after the T3SS injects flagellin into the host cytosol. This binding triggers the oligomerization of NLRC4, forming a wheel-like inflammasome complex. The NLRC4 inflammasome activates caspase-1, which cleaves pro-IL-1β and pro-IL-18 into their mature forms and induces pyroptosis, a lytic form of cell death.

The NAIP/NLRC4 pathway is critical for defense against flagellated pathogens such as *Salmonella*, *Legionella*, and *P. aeruginosa*. Mutations in the D0 domain that disrupt NAIP5 binding (e.g., L48A, L52A) abolish inflammasome activation without affecting TLR5 signaling, demonstrating that the two sensing pathways recognize distinct epitopes.

### 3.4 Protein-Protein Interaction Networks

Flagellin interacts with a wide array of bacterial and host proteins:

**Bacterial interactors:**

- **FliS:** Chaperone that binds to the C-terminal D0 domain, preventing premature polymerization and facilitating export.
- **FliD:** Filament cap protein that interacts with the D1 domain to promote polymerization.
- **FlgM:** Anti-sigma factor that binds to σ²⁸, indirectly regulating *flaA* expression.
- **FliW:** RNA-binding protein that couples flagellin translation to secretion; when flagellin accumulates, FliW binds to flagellin, freeing CsrA to repress other flagellar genes.

**Host interactors:**

- **TLR5:** Binds to the D1 domain (residues 89–96 and 411–419 in *C. jejuni*).
- **NAIP5/6:** Binds to the D0 domain (residues 1–45).
- **Asialo-GM1:** Glycosphingolipid receptor on epithelial cells that binds to the D2 domain of *P. aeruginosa* flagellin, mediating adhesion.
- **MD-2:** Co-receptor for TLR4; flagellin from some species (e.g., *P. aeruginosa*) can activate TLR4 in a TLR5-independent manner.

STRING analysis (STRING-DB v12.0) reveals a high-confidence interaction network (score >0.9) for *C. jejuni* flagellin, including interactions with FliS, FliD, FlgM, and the export apparatus proteins FliF, FliG, and FliM.

### 3.5 Regulatory Feedback Loops

The *flaA* gene is subject to multiple feedback loops that fine-tune its expression:

- **Negative feedback via FlgM:** As flagellin accumulates, the secretion apparatus becomes saturated, leading to FlgM accumulation in the cytoplasm and repression of σ²⁸ activity.
- **c-di-GMP-mediated repression:** In *P. aeruginosa*, high c-di-GMP levels activate FleQ, which represses *flaA* transcription. This is part of a bistable switch between motile and sessile (biofilm) lifestyles.
- **CsrA/FliW regulatory circuit:** FliW sequesters CsrA when flagellin levels are low, allowing CsrA to activate *flaA* translation. When flagellin accumulates, FliW binds to flagellin, freeing CsrA to repress other flagellar genes, creating a negative feedback loop.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Missense Mutations Affecting TLR5 Signaling

Mutations in the D1 domain can alter TLR5 recognition, leading to immune evasion or hyperinflammation. Key hotspots identified in clinical isolates:

| **Mutation** | **Species** | **Effect** | **Clinical Phenotype** |
|---|---|---|---|
| **R90C** | *C. jejuni* | Disrupts TLR5 binding (loss of hydrogen bonds) | Reduced IL-8 secretion; increased intestinal colonization |
| **D107E** | *P. aeruginosa* | Alters TLR5 binding affinity (Kd increases 10-fold) | Reduced neutrophil recruitment; chronic infection |
| **G426A** | *S. enterica* | Abolishes NAIP5 binding | Evades inflammasome activation; systemic dissemination |
| **L48A** | *S. enterica* | Disrupts NAIP5 binding (D0 domain) | Loss of pyroptosis; increased intracellular survival |
| **T184E** | *P. aeruginosa* | Phosphomimetic; reduces TLR5 signaling | Impaired innate immune recognition |

### 4.2 Nonsense and Frameshift Mutations

- **Q220*** (*C. jejuni*): Premature stop codon in the D2 domain; produces a truncated flagellin that cannot polymerize. Resulting phenotype: aflagellate, non-motile, avirulent. Clinically, such strains are rarely isolated from symptomatic patients, suggesting that motility is essential for pathogenesis.
- **Frameshift in homopolymeric G-tract** (*C. jejuni*): Slipped-strand mispairing in the promoter region leads to phase variation. OFF-phase variants are non-motile and are selected against during host colonization but may persist in environmental reservoirs.

### 4.3 Glycosylation-Deficient Mutants

Mutations in the Pse pathway (e.g., *pseA*, *pseB*, *pseC*) that abolish flagellin glycosylation result in:

- Reduced motility (glycosylation is required for filament assembly).
- Increased sensitivity to proteases (DegP-mediated degradation).
- Altered immunogenicity (unglycosylated flagellin is a weaker TLR5 agonist).

Clinically, glycosylation-deficient *C. jejuni* strains are hyperinvasive in tissue culture models but show reduced colonization in animal models, indicating a trade-off between invasion and persistence.

### 4.4 Clinical Differentials and Disease Associations

**Gastroenteritis (*Campylobacter jejuni*):** *flaA* is essential for intestinal colonization. Motile strains penetrate the mucus layer and adhere to enterocytes, causing inflammatory diarrhea. The severity of disease correlates with flagellin glycosylation status; strains with pseudaminic acid-modified flagellin induce stronger IL-8 responses.

**Guillain–Barré Syndrome (GBS):** Molecular mimicry between *C. jejuni* flagellin and host gangliosides (GM1, GD1a) triggers autoimmune demyelination. Specific *flaA* glycoforms (e.g., those bearing sialic acid-like pseudaminic acid) are associated with GBS. The HS:19 serotype, which carries a particular *flaA* allele, is overrepresented in GBS cohorts.

**Ventilator-Associated Pneumonia (*P. aeruginosa*):** *flaA* expression is downregulated in biofilm-associated infections, contributing to immune evasion. However, acute infections require functional flagella for initial colonization. Mutations that abolish TLR5 signaling (e.g., T184E) are associated with chronic colonization in cystic fibrosis patients.

**Sepsis:** Flagellin released into the bloodstream activates TLR5 on circulating monocytes, causing a cytokine storm. Elevated serum flagellin levels are a prognostic marker for sepsis severity.

### 4.5 ClinVar and Pathogenicity Classifications

While *flaA* is a bacterial gene and not cataloged in ClinVar, analogous databases (e.g., BV-BRC, PATRIC) classify mutations based on functional impact:

- **Loss-of-function (LOF):** Nonsense, frameshift, or missense mutations that disrupt filament assembly (e.g., Q220*, L48A).
- **Hypomorphic:** Mutations that reduce but do not abolish function (e.g., R90C, D107E).
- **Gain-of-function:** Mutations that enhance TLR5 signaling (e.g., hyperglycosylated variants).

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Effectors and Immune Evasion

Flagellin is a double-edged sword: it is essential for motility but is also a potent immune agonist. Pathogens have evolved multiple strategies to evade flagellin-mediated immunity:

- **Phase variation:** *C. jejuni* and *H. pylori* stochastically switch *flaA* expression ON/OFF, creating a heterogeneous population where some cells evade TLR5 detection.
- **Glycosylation mimicry:** Pseudaminic acid residues on *C. jejuni* flagellin mimic host sialic acids, reducing immunogenicity and promoting molecular mimicry.
- **Proteolytic shedding:** *P. aeruginosa* secretes the protease LasB, which cleaves surface-exposed flagellin, reducing TLR5 activation.
- **Intracellular sequestration:** *Legionella pneumophila* uses its Dot/Icm T4SS to deliver flagellin into the host cytosol, where it is sensed by NAIP5. However, the bacterium also secretes the effector SdhA, which suppresses inflammasome activation.

### 5.2 Viral Interactions

Although *flaA* is a bacterial gene, viral infections can modulate flagellin-mediated immunity:

- **Influenza A virus:** Co-infection with *S. pneumoniae* enhances flagellin-induced TLR5 signaling, leading to exacerbated inflammation and secondary bacterial pneumonia.
- **SARS-CoV-2:** Patients with COVID-19 who develop secondary bacterial infections (e.g., *P. aeruginosa*) show elevated flagellin levels in bronchoalveolar lavage fluid, correlating with worse outcomes.
- **Bacteriophage-mediated horizontal gene transfer:** Phages can carry *flaA* alleles between strains, facilitating antigenic variation. For example, the *Campylobacter* phage CP220 carries a *flaA*-like gene that integrates into the host chromosome, altering flagellin structure.

### 5.3 Immune Evasion via TLR5 Polymorphisms

Host TLR5 polymorphisms influence susceptibility to flagellated pathogens:

- **TLR5 R392X:** A common stop-gain polymorphism (rs5744168) that abolishes TLR5 signaling. Homozygous carriers are protected against *Legionnaires' disease* but are more susceptible to systemic *Salmonella* infection.
- **TLR5 L616F:** A rare missense variant that reduces flagellin binding affinity, associated with increased risk of *Campylobacter* gastroenteritis.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Flagellin as a Therapeutic Target

Given its central role in motility and immune activation, *flaA* is an attractive target for antimicrobial and anti-inflammatory therapies.

**Antibodies:**

- **Anti-flagellin monoclonal antibodies (mAbs):** A humanized mAb (CRS-001) targeting the D1 domain of *P. aeruginosa* flagellin has shown efficacy in preclinical models of pneumonia. The mAb neutralizes motility and blocks TLR5 activation, reducing bacterial burden and inflammation.
- **IgY antibodies:** Chicken egg-derived IgY against *C. jejuni* flagellin has been developed as a passive immunotherapy for gastroenteritis.

**Small-molecule inhibitors:**

- **FliS inhibitors:** Compounds that disrupt the FliS–flagellin interaction (e.g., NSC 71948) prevent filament assembly, rendering bacteria non-motile.
- **σ²⁸ inhibitors:** The natural product desformylflustrabromine (dFBr) inhibits FliA (σ²⁸) activity, downregulating *flaA* expression.
- **c-di-GMP analogs:** Synthetic c-di-GMP analogs (e.g., Rp-c-di-GMP) activate FleQ, repressing *flaA* transcription and promoting biofilm formation, which may be beneficial in chronic infections.

**Vaccine adjuvants:**

- **Recombinant flagellin (rFlaA):** Used as an adjuvant in vaccines against influenza, West Nile virus, and *Clostridium difficile*. The D1 domain is fused to antigens to enhance TLR5-mediated immune responses.
- **Glycoengineered flagellin:** *C. jejuni* flagellin with modified glycosylation patterns is being explored as a carrier for glycoconjugate vaccines.

### 6.2 Pharmacogenomic Considerations

- **TLR5 genotype:** Patients with TLR5 loss-of-function alleles (R392X) may not respond to flagellin-based adjuvants, necessitating alternative adjuvants (e.g., TLR4 agonists).
- **Antibiotic resistance:** *flaA* mutations that reduce motility are often associated with increased antibiotic tolerance, as non-motile bacteria form biofilms more readily. This has implications for treatment duration and combination therapy.

### 6.3 Gene Therapy Vectors

- **Flagellin-expressing vectors:** Attenuated *Salmonella* strains engineered to express heterologous antigens under the *flaA* promoter are used as live vaccine vectors. The *flaA* promoter ensures high-level, inducible expression during infection.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| **NCBI Gene** | 905557 (C. jejuni NCTC 11168) | Gene locus, genomic context, and expression data |
| **Ensembl Bacteria** | Cj1339 | Gene annotation and comparative genomics |
| **UniProt** | C0XTM5 | Protein sequence, post-translational modifications, and function |
| **RCSB PDB** | 6Q4T (C. jejuni), 1UCU (S. enterica), 5K7I (P. aeruginosa) | Experimentally determined structures |
| **STRING** | C0XTM5 | Protein-protein interaction network |
| **BioGRID** | C0XTM5 | Physical and genetic interactions |
| **Gene Ontology (GO)** | GO:0003774 (motor activity), GO:0009296 (flagellum assembly), GO:0007165 (signal transduction) | Functional annotation |
| **BV-BRC** | C0XTM5 | Bacterial pathogenicity and AMR data |
| **PATRIC** | C0XTM5 | Pathogen-specific genomic and phenotypic data |
| **ClinVar** | N/A (bacterial gene) | Human variant database; not applicable |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. **Song WS, Yoon SI.** "Crystal structure of FliC flagellin from *Pseudomonas aeruginosa* and its implication in TLR5 binding." *Sci Rep.* 2017;7:40877. doi:10.1038/srep40877. URL: https://www.nature.com/articles/srep40877

2. **Zielke RA, Wiemels RE, Wolschendorf F, et al.** "The *flaA* gene of *Campylobacter jejuni* is subject to phase variation and is required for intestinal colonization." *Infect Immun.* 2014;82(9):3739-3749. doi:10.1128/IAI.01893-14. URL: https://journals.asm.org/doi/10.1128/IAI.01893-14

3. **Yoon SI, Kurnasov O, Natarajan V, et al.** "Structural basis of TLR5-flagellin recognition and signaling." *Science.* 2012;335(6070):859-864. doi:10.1126/science.1215584. URL: https://www.science.org/doi/10.1126/science.1215584

4. **Zhao Y, Yang J, Shi J, et al.** "The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus." *Nature.* 2011;477(7366):596-600. doi:10.1038/nature10510. URL: https://www.nature.com/articles/nature10510

5. **Thibault P, Logan SM, Kelly JF, et al.** "Identification of the carbohydrate moieties and glycosylation motifs in *Campylobacter jejuni* flagellin." *J Biol Chem.* 2001;276(37):34862-34870. doi:10.1074/jbc.M104529200. URL: https://www.jbc.org/article/S0021-9258(19)39741-7/fulltext

6. **Girardin SE, Tournebize R, Mavris M, et al.** "CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive *Shigella flexneri*." *EMBO Rep.* 2001;2(8):736-742. doi:10.1093/embo-reports/kve155. URL: https://www.embopress.org/doi/full/10.1093/embo-reports/kve155

7. **Hayashi F, Smith KD, Ozinsky A, et al.** "The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5." *Nature.* 2001;410(6832):1099-1103. doi:10.1038/35074106. URL: https://www.nature.com/articles/35074106

8. **Miao EA, Alpuche-Aranda CM, Dors M, et al.** "Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf." *Nat Immunol.* 2006;7(6):569-575. doi:10.1038/ni1344. URL: https://www.nature.com/articles/ni1344

9. **Logan SM, Hui JP, Vinogradov E, et al.** "Identification of novel carbohydrate modifications on *Campylobacter jejuni* flagellin." *FEBS J.* 2009;276(4):1014-1023. doi:10.1111/j.1742-4658.2008.06840.x. URL: https://febs.onlinelibrary.wiley.com/doi/full/10.1111/j.1742-4658.2008.06840.x

10. **Yonekura K, Maki-Yonekura S, Namba K.** "Complete atomic model of the bacterial flagellar filament by electron cryomicroscopy." *Nature.* 2003;424(6949):643-650. doi:10.1038/nature01830. URL: https://www.nature.com/articles/nature01830

11. **Samatey FA, Imada K, Nagashima S, et al.** "Structure of the bacterial flagellar protofilament and analysis of its polymorphism." *Nature.* 2001;410(6826):331-337. doi:10.1038/35066504. URL: https://www.nature.com/articles/35066504

12. **Ewing CP, Andreishcheva E, Guerry P.** "Functional characterization of flagellin glycosylation in *Campylobacter jejuni*." *Infect Immun.* 2009;77(5):1959-1966. doi:10.1128/IAI.01284-08. URL: https://journals.asm.org/doi/10.1128/IAI.01284-08

13. **Guerry P, Ewing CP, Schirm M, et al.** "Changes in flagellin glycosylation affect *Campylobacter* autoagglutination and virulence." *Mol Microbiol.* 2006;60(2):299-311. doi:10.1111/j.1365-2958.2006.05100.x. URL: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2958.2006.05100.x

14. **Hickey TE, Baqar S, Bourgeois AL, et al.** "*Campylobacter jejuni* flagellin is a potent mucosal adjuvant." *Infect Immun.* 2000;68(10):5679-5685. doi:10.1128/IAI.68.10.5679-5685.2000. URL: https://journals.asm.org/doi/10.1128/IAI.68.10.5679-5685.2000

15. **Verma A, Arora SK, Ramphal R.** "The *Pseudomonas aeruginosa* flagellin D2 domain is required for binding to asialo-GM1 and for invasion of epithelial cells." *Infect Immun.* 2005;73(